Advertisement
Screener

EVOFEM BIOSCIENCES, INC. (EVFM) Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Tax and Reclassification Adjustment

1.9 / 5 stars · 29/78 Roast Me

EVOFEM BIOSCIENCES, INC. Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Tax and Reclassification Adjustment

EVOFEM BIOSCIENCES, INC. (EVFM) reported Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Tax and Reclassification Adjustment of -$934.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Income Statement › Unrealized Gains

us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment · last filed 2026-08-14

  • EVOFEM BIOSCIENCES, INC. other comprehensive income (loss), financial liability, fair value option, after tax and reclassification adjustment for the quarter ending 2026-06-30 was -$934.00K.
  • EVOFEM BIOSCIENCES, INC. other comprehensive income (loss), financial liability, fair value option, after tax and reclassification adjustment for the quarter ending 2026-03-31 was $2.17M, a 236.17% increase year-over-year.
  • EVOFEM BIOSCIENCES, INC. other comprehensive income (loss), financial liability, fair value option, after tax and reclassification adjustment for the quarter ending 2025-12-31 was -$2.10M.
  • EVOFEM BIOSCIENCES, INC. other comprehensive income (loss), financial liability, fair value option, after tax and reclassification adjustment for the quarter ending 2025-09-30 was -$4.16M.
  • EVOFEM BIOSCIENCES, INC. other comprehensive income (loss), financial liability, fair value option, after tax and reclassification adjustment for fiscal 2025 was -$6.19M.
  • EVOFEM BIOSCIENCES, INC. other comprehensive income (loss), financial liability, fair value option, after tax and reclassification adjustment for fiscal 2024 was -$1.92M, a 108.43% decline from fiscal 2023.
  • EVOFEM BIOSCIENCES, INC. other comprehensive income (loss), financial liability, fair value option, after tax and reclassification adjustment for fiscal 2023 was $22.81M, a 48.66% decline from fiscal 2022.
  • EVOFEM BIOSCIENCES, INC. other comprehensive income (loss), financial liability, fair value option, after tax and reclassification adjustment for fiscal 2022 was $44.44M, a 773.22% increase from fiscal 2021.
Period endOther Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Tax and Reclassification Adjustment 3 monthOther Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Tax and Reclassification Adjustment 6 monthOther Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Tax and Reclassification Adjustment 9 monthOther Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Tax and Reclassification Adjustment 12 month
2026-06-30-$934.00K
10-Q · filed 2026-08-14
$1.24M
10-Q · filed 2026-08-14
-$859.00K
derived: sum of 3 quarters · filed 2026-08-14
-$5.02M
derived: sum of 4 quarters · filed 2026-08-14
2026-03-31$2.17M
10-Q · filed 2026-08-14
$75.00K
derived: sum of 2 quarters · filed 2026-08-14
-$4.09M
derived: sum of 3 quarters · filed 2026-08-14
-$4.66M
derived: sum of 4 quarters · filed 2026-08-14
2025-12-31-$2.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11
-$6.26M
derived: sum of 2 quarters · filed 2026-03-11
-$6.83M
derived: sum of 3 quarters · filed 2026-08-14
-$6.19M
10-K · filed 2026-03-11
2025-09-30-$4.16M
10-Q · filed 2025-11-13
-$4.74M
derived: sum of 2 quarters · filed 2026-08-14
-$4.09M
10-Q · filed 2025-11-13
-$5.01M
derived: sum of 4 quarters · filed 2026-08-14
2025-06-30-$573.00K
10-Q · filed 2026-08-14
$74.00K
10-Q · filed 2026-08-14
-$849.00K
derived: sum of 3 quarters · filed 2026-08-14
-$1.92M
derived: sum of 4 quarters · filed 2026-08-14
2025-03-31$647.00K
10-Q · filed 2026-08-14
-$276.00K
derived: sum of 2 quarters · filed 2026-08-14
-$1.34M
derived: sum of 3 quarters · filed 2026-08-14
-$1.60M
derived: sum of 4 quarters · filed 2026-08-14
2024-12-31-$923.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11
-$1.99M
derived: sum of 2 quarters · filed 2026-03-11
-$2.25M
derived: sum of 3 quarters · filed 2026-03-11
-$1.92M
10-K · filed 2026-03-11
2024-09-30-$1.07M
10-Q · filed 2025-11-13
-$1.32M
derived: sum of 2 quarters · filed 2025-11-13
-$1.00M
10-Q · filed 2025-11-13
-$1.56M
derived: sum of 4 quarters · filed 2025-11-13
2024-06-30-$256.00K
10-Q · filed 2025-11-13
$68.00K
10-Q · filed 2025-08-14
-$491.00K
derived: sum of 3 quarters · filed 2025-11-13
-$946.00K
derived: sum of 4 quarters · filed 2025-11-13
2024-03-31$324.00K
10-Q · filed 2025-11-13
-$235.00K
derived: sum of 2 quarters · filed 2025-11-13
-$690.00K
derived: sum of 3 quarters · filed 2025-11-13
$7.68M
derived: sum of 4 quarters · filed 2025-11-13
2023-12-31-$559.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24
-$1.01M
derived: sum of 2 quarters · filed 2025-03-24
$7.35M
derived: sum of 3 quarters · filed 2025-03-24
$22.81M
10-K · filed 2025-03-24
2023-09-30-$455.00K
10-Q · filed 2024-11-14
$7.91M
derived: sum of 2 quarters · filed 2024-11-14
$23.37M
10-Q · filed 2024-11-14
$35.94M
derived: sum of 4 quarters · filed 2024-11-14
2023-06-30$8.37M
10-Q · filed 2024-11-14
$23.83M
10-Q · filed 2024-08-14
$36.40M
derived: sum of 3 quarters · filed 2024-11-14
$71.76M
derived: sum of 4 quarters · filed 2024-11-14
2023-03-31$15.46M
10-Q · filed 2024-11-14
$28.03M
derived: sum of 2 quarters · filed 2024-11-14
$63.39M
derived: sum of 3 quarters · filed 2024-11-14
$59.72M
derived: sum of 4 quarters · filed 2024-11-14
2022-12-31$12.57M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27
$47.93M
derived: sum of 2 quarters · filed 2024-03-27
$44.26M
derived: sum of 3 quarters · filed 2024-03-27
$44.44M
10-K · filed 2024-03-27
2022-09-30$35.36M
10-Q · filed 2023-11-14
$31.69M
derived: sum of 2 quarters · filed 2023-11-14
$31.87M
10-Q · filed 2023-11-14
$31.87M
derived: sum of 4 quarters · filed 2023-11-14
2022-06-30-$3.67M
10-Q · filed 2023-11-14
-$3.49M
10-Q · filed 2023-08-14
-$3.49M
derived: sum of 3 quarters · filed 2023-11-14
$1.59M
derived: sum of 4 quarters · filed 2023-11-14
2022-03-31$181.00K
10-Q · filed 2023-11-14
$181.00K
derived: sum of 2 quarters · filed 2023-11-14
$5.27M
derived: sum of 3 quarters · filed 2023-11-14
$5.27M
derived: sum of 4 quarters · filed 2023-11-14
2021-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-27
$5.09M
derived: sum of 2 quarters · filed 2023-04-27
$5.09M
derived: sum of 3 quarters · filed 2023-04-27
$5.09M
10-K · filed 2023-04-27
2021-09-30$5.09M
10-Q · filed 2023-01-06
$5.09M
derived: sum of 2 quarters · filed 2023-01-06
$5.09M
10-Q · filed 2023-01-06
$5.09M
derived: sum of 4 quarters · filed 2023-01-06
2021-06-30$0.00
10-Q · filed 2022-08-12
$0.00
10-Q · filed 2022-08-12
$0.00
derived: sum of 3 quarters · filed 2022-08-12
$0.00
derived: sum of 4 quarters · filed 2022-08-12
2021-03-31$0.00
10-Q · filed 2022-05-10
$0.00
derived: sum of 2 quarters · filed 2022-05-10
$0.00
derived: sum of 3 quarters · filed 2022-05-10
2020-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10
$0.00
derived: sum of 2 quarters · filed 2022-03-10
$0.00
10-K · filed 2022-03-10
2020-09-30$0.00
10-Q · filed 2021-11-15
$0.00
10-Q · filed 2021-11-15